Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods – 15 August 2023

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was introduced to regulate the quality, efficacy, and safety of therapeutic goods, including medicines, medical devices, and blood products, within the country. The Act aims to protect public health by ensuring that therapeutic goods available in Australia meet the necessary standards. It establishes a framework for the approval, manufacture, and distribution of these goods, overseen by the Therapeutic Goods Administration (TGA). This legislative instrument, published on 15 August 2023, serves to notify the public of licences granted to specific manufacturers of therapeutic goods, thereby ensuring transparency and adherence to regulatory standards. The policy objective underpinning this Act is to safeguard the health and safety of the Australian public by maintaining stringent controls over the therapeutic goods market. The Therapeutic Goods Administration, as the delegate of the Secretary of the Department of Health and Aged Care, publishes the list of manufacturers granted licences for the manufacture of therapeutic goods under Section 38 of the Therapeutic Goods Act 1989. This publication, dated 15 August 2023, includes details of licences granted to specific entities such as Scientest Analytical Services Pty Ltd, Australian Red Cross Lifeblood, and Cannatrek Medical Pty Ltd, thereby ensuring compliance with regulatory requirements and providing the public with the necessary information about the entities responsible for manufacturing therapeutic goods in Australia.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, which encompasses a wide range of products including medicines, medical devices, blood, tissues, and other related products. This Act applies to persons and entities involved in the manufacture, supply, importation, and advertising of therapeutic goods. The legislation covers various industries including pharmaceuticals, biotechnology, and medical device manufacturing, ensuring that these products meet quality, safety, and efficacy standards. The Act's jurisdictional reach is national, operating under the Commonwealth but also in conjunction with state and territory regulations. It mandates licences for manufacturing therapeutic goods, and the publication of a list of licence holders ensures transparency and accountability. There are specific exclusions and exemptions provided under the Act, such as certain over-the-counter products and those used solely for personal use. The Act also extends its application through subordinate instruments, which provide detailed regulations and standards that complement the primary legislation.

Key Provisions

The Therapeutic Goods Act 1989, under Section 38, provides for the issuance of licences to entities that are authorised to manufacture therapeutic goods in Australia. Section 38 requires the Secretary of the Department of Health and Aged Care, through the Therapeutic Goods Administration (TGA), to grant these licences to entities that meet the specified standards and requirements. The recent publication of the list of manufacturers granted licence (Gazette C2023G00968) includes three entities: ScienteST Analytical Services Pty Ltd (Licence No. MI-2023-LI-02576-1), Australian Red Cross Lifeblood (Licence No. MI-2023-LI-00821-1), and CannaTrek Medical Pty Ltd (Licence No. MI-2022-LI-15831-1). Each entity listed has been granted the authority to manufacture therapeutic goods in accordance with the provisions of the Act. Entities granted a manufacturing licence under the Therapeutic Goods Act 1989 are subject to stringent obligations and requirements. These obligations include maintaining appropriate quality control systems, adhering to good manufacturing practices, and ensuring that all therapeutic goods produced meet the standards outlined in the Therapeutic Goods Regulations 1990. Additionally, licensed manufacturers must submit regular reports to the TGA, providing detailed information on the production processes, quality assurance measures, and any incidents or adverse events related to the therapeutic goods they manufacture. The entities must also ensure that their facilities comply with any relevant Australian standards and guidelines. Failure to comply with the requirements of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in significant consequences. Breaches of the Act may lead to the suspension or revocation of a manufacturing licence, which can have serious implications for the entity's ability to operate in the Australian market. In addition to administrative penalties, the Act also provides for criminal offences where there is evidence of wilful or negligent conduct. Individuals and entities found guilty of contravening the Act can face substantial fines, with the maximum penalty for corporate entities being $2,100,000 under Section 32DA of the Act. Furthermore, individuals responsible for the contravention may face imprisonment, with the maximum penalty being 5 years under Section 32DB. These stringent penalties are designed to ensure high standards of quality and safety in the manufacture of therapeutic goods within Australia.